Icure Pharmaceutical Incorporation
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Icure Pharmaceutical makes medicated skin patches, adhesive drug-delivery systems worn on the body, as well as skincare and sheet-mask products manufactured under contract for other brands.
It supplies pharmaceutical customers and cosmetics companies, and is listed on KOSDAQ, South Korea's tech and small-cap exchange. The large majority of its revenue comes from the cosmetics contract-manufacturing business, while its pharmaceutical segment is anchored by a patch-form treatment for Alzheimer's disease.
Summary is AI-generated and may contain errors · figures from DART filings
The company has signed overseas licensing and supply agreements for its Alzheimer's patch with Menarini and Celltrion, both named in its filing.
Icure Pharmaceutical Incorporation in five facts
What does Icure Pharmaceutical Incorporation do?
Icure Pharmaceutical makes medicated skin patches, adhesive drug-delivery systems worn on the body, as well as skincare and sheet-mask products manufactured under contract for other brands.
Where is Icure Pharmaceutical Incorporation listed and in which sector?
Icure Pharmaceutical Incorporation (Korean name: 아이큐어) trades under KRX code 175250 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Materials sector, Chemicals.
How large is Icure Pharmaceutical Incorporation?
Its market capitalisation was US$69.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Icure Pharmaceutical Incorporation's latest annual revenue and operating profit?
For fiscal year 2025, Icure Pharmaceutical Incorporation reported revenue of US$62.9M, an operating loss of US$9M and a net loss of US$26.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 20.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Half-year report (2026.06)Oct 20
- [Amended] Half-year report (2026.06)Oct 20
- [Amended] Report on large shareholdings (5% rule) (standard)Oct 7
- Report on large shareholdings (5% rule) (standard)Oct 7
- Report on securities held by executives/major shareholdersSep 30
- [Amended] Half-year report (2026.06)Sep 18
- Report on securities held by executives/major shareholdersSep 15
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 9
- Report on securities held by executives/major shareholdersSep 9
- Share-pledge agreement that may change the largest shareholder
Icure Pharmaceutical Incorporation's largest shareholder (Solum Cosmetic Co., Ltd.) pledged shares as loan collateral, securing up to US$20.7M.
Ownership change · Sep 4 - Report on securities held by executives/major shareholdersSep 4
- Report on large shareholdings (5% rule) (standard)Sep 4
- Other management matter (voluntary)Sep 3
- [Amended] Change of largest shareholder
Icure Pharmaceutical Incorporation amends its August 28, 2026 change-of-largest-shareholder disclosure, extending the mandatory holding period for the 18,858,802 new shares acquired by Solumeu Cosmetics Co., Ltd. from 1 year to 3 years following a September 2, 2026 listing-maintenance decision by the KOSDAQ Listed Company Examination Committee; the largest shareholder changed from Choi Young-kwon (5,663,353 shares, 15.08%) to Solumeu Cosmetics Co., Ltd. and 2 others (24,177,949 shares, 39.16%) upon completion of payment for a third-party-placement rights offering.
Ownership change · Sep 3 · 3 versions - [Amended] Securities issuance results (voluntary)
Icure Pharmaceutical Incorporation amends its August 28, 2026 voluntary securities issuance results disclosure to correct the listing date of the new shares from September 11, 2026 to September 10, 2026, and notes that the mandatory holding period for the 18,858,802 shares acquired by Solumeu Cosmetics Co., Ltd. was extended from 1 year to 3 years following a September 2, 2026 listing-maintenance decision; the third-party-placement rights offering issued 24,177,949 shares for US$18.4M, fully paid on August 28, 2026.
Capital raise · Sep 3 - [Amended] Material event report (rights offering)
Icure Pharmaceutical Incorporation updated the terms of a private placement (third-party allotment) to raise US$18.4M, about 24.5% of its market value.
Capital raise · Sep 3 · 8 versions - Trading suspension liftedSep 2
- Other market noticeSep 2
- Share-pledge agreement tied to the largest shareholder terminated/cancelled
A previously disclosed share pledge on Icure Pharmaceutical Incorporation's largest shareholder (an individual) was released or cancelled, freeing collateral of US$8.52M.
Ownership change · Sep 1 - [Amended] Securities issuance results (voluntary)Aug 31